Literature DB >> 6687414

The accumulation of [35S]methimazole by human and rat lymphocytes.

G S Shewring, J H Lazarus.   

Abstract

The accumulation of 35S labelled methimazole (MMI) was examined in lymphocytes. No uptake of label was found in peripheral blood lymphocytes (PBL) from normal control subjects after in vitro incubation with the drug. Following administration of [35S]MMI to patients with Graves' hyperthyroidism PBL cell to plasma (C/P) 35S activity was greater than 1 in 4 of 11 patients and only in 1 of 7 other patients undergoing thyroidectomy. Thyroid lymphocytes from 2 of these patients showed some accumulation of activity. Following administration of [35S]MMI to normal rats C/P 35S ratios ranged from 1-5.6 but no 35S accumulation was found in PBL or thyroid lymphocytes from August strain rats in which experimental autoimmune thyroiditis had been produced. It is concluded that there is minimal, if any, significant accumulation of MMI in lymphocytes of patients with Graves' disease. The immunosuppressive action of MMI on lymphocyte antibody production must therefore by indirect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6687414     DOI: 10.1530/acta.0.1020068

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

1.  Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression.

Authors:  A P Weetman; M E Holt; A K Campbell; R Hall; A M McGregor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

2.  Inhibition of the receptor for interleukin-2 induced by carbimazole: relevance for the therapy of autoimmune thyroid disease.

Authors:  A Signore; P Pozzilli; U Di Mario; M Sensi; P Beales; D Andreani
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

3.  Thyroxine, methimazole, and thyroid microsomal autoantibody titres in hypothyroid Hashimoto's thyroiditis.

Authors:  R Jansson; A Karlsson; P A Dahlberg
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.